UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000029962
Receipt No. R000034226
Scientific Title Clinical trial of mesenchymal stem cell mobilization factor KOI2 in epidermolysis bullosa patients
Date of disclosure of the study information 2017/11/30
Last modified on 2019/05/29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Clinical trial of mesenchymal stem cell mobilization factor KOI2 in epidermolysis bullosa patients
Acronym Clinical trial of KOI2 in epidermolysis bullosa patients
Scientific Title Clinical trial of mesenchymal stem cell mobilization factor KOI2 in epidermolysis bullosa patients
Scientific Title:Acronym Clinical trial of KOI2 in epidermolysis bullosa patients
Region
Japan

Condition
Condition epidermolysis bullosa
Classification by specialty
Dermatology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Primary objective
Evaluation of efficacy of KOI2 in epidermolysis bullosa
Secondary objective
Evaluation of safety of KOI2 in epidermolysis bullosa
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Change rate of total area of blisters, erosions and ulcers compared to those of base line
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 KOI2 1mg/kg drip infusion administration for 30 minutes. First week; once per day for four days, second- to forth-week; twice per week (at least once in three to four days).
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Patients understands the protocol and agrees to provide written informed consent to participate in the study on a voluntary basis. For patient under 20-year old, informed consent of voluntary participation should be obtained by a legal guardian. Informed assent is collected, if possible, with a patient more than 7-year old.
(2) Patients who are confirmed at the present day or before to satisfy following item number 1, and at least one item out of the following number 2 to 5.
1. Blister, erosion, and/or ulcer formations induced by daily minor trauma have been continued on the skin and oral mucosa from beginning of the birth or from 0~6 year old.
2. Existence of patient(s) suffering from dystrophic epidermolysis bullosa in the family member.
3. Intradermal blister formation right beneath the basement membrane has been confirmed by histological study.
4. Decrease or absence of type VII collagen at the cutaneous basement membrane zone has been confirmed by immunofluorescent study.
5. Mutation of type VII collagene gene (COL7A1) has been identified.

(3) Total area of vesicles, erosions and ulcers is more than 20 cm2 at the timing of obtaining informed consent. The size of each vesicle, erosion and/or ulcer is measured by length x width using a vernier caliper (Large size can be measured by a ruler). The sum of the areas for the whole body is calculated, excluding those under 2 mm by length.
(4) Patient agrees to take appropriate birth control measures from day 1 through 1 month after the last drug administration (including condom, birth control by female partner, and/or others).

(5) A woman of childbearing potential, agrees to use a highly effective method of contraception from screening visit through 1 month after the last drug administration.
Key exclusion criteria Epidermolysis bullosa other than malnutrition type
(2) Urine pregnancy test is positive (female only) at screening visit
(3) Breast feeding female patient
(4) HIV, HBs, HCV positive at screening
(5) A subject who participated in other clinical trials within 90 days and received a clinical trial drug (including a placebo)
(6) A subject who is participating in any other clinical trials.
(7) A subject whose liver dysfunction data match the predefined exclusion standard
(8) A subject who has acute worsening of epidermolysis bullosa (such as tracheal/esophageal stenosis, acute nephritis)
(9) Ineligible by other reasons judged by the investigators
Target sample size 8

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Atsushi Tanemura
Organization Osaka University Hospital
Division name Dermatology
Zip code
Address 2-15, Yamadaoka, Suita-shi, Osaka 565-0871, Japan
TEL 06-6879-3902
Email tanemura8@hotmail.co.jp

Public contact
Name of contact person
1st name
Middle name
Last name Yoko Kawamura
Organization Osaka University Hospital
Division name Department of Medical Innovation
Zip code
Address 2-2, Yamadaoka, Suita-shi, Osaka 565-0871, Japan
TEL 06-6210-8289
Homepage URL
Email kawamura@dmi.med.osaka-u.ac.jp

Sponsor
Institute Osaka University Hospital
Institute
Department

Funding Source
Organization Japan Agency for Medical Research and Development/Shionogi & Co., Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor Toho University Omori Medical Center
Name of secondary funder(s) Keio University Hospital

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2017 Year 11 Month 30 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 9
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2017 Year 11 Month 30 Day
Date of IRB
2017 Year 10 Month 24 Day
Anticipated trial start date
2018 Year 01 Month 01 Day
Last follow-up date
2019 Year 09 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 11 Month 14 Day
Last modified on
2019 Year 05 Month 29 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034226

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.